Literature DB >> 27363693

Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson's disease.

Dronacharya Lamichhane1, Ann L Gruber-Baldini2, Stephen G Reich3, Lisa M Shulman4.   

Abstract

PURPOSE: Clinical trials in Parkinson's disease commonly employ outcome measures of disability and quality of life. Responsiveness of these outcomes measures to symptomatic decline versus improvement has not been studied. We wanted to study the responsiveness of Schwab & England Activities of Daily Living Scale (SE) and Short Form-12 (SF-12) to symptomatic decline versus improvement in Parkinson's disease over a 4-year period among a naturalistic cohort of patients.
METHODS: Parkinson's disease patients (N = 228, disease duration 6.1 years) were followed for 4 years with assessments of disease severity, Unified Parkinson's Disease Rating Scale (UPDRS), health-related quality of life (SF-12 physical/mental health), and disability (SE). The sample was subdivided into those who declined (N = 118) or improved (N = 102) on total-UPDRS. Responsiveness was assessed with Cohen's effect size and standardized response mean.
RESULTS: At baseline, patients who improved over 4 years had greater disease severity and worse quality of life than decliners (p < .05). Decliners had a 13.5-point worsening on total-UPDRS, 26.3-39.8; p < .001) associated with concomitant decline on the SF-12 (physical health 42.9-39.2, mental health 50.0-46.6; both p < .001) and the SE (85-74 %; p < .001). Improvers had a 13.0-point improvement on total-UPDRS (39.8-26.8; p < .001) associated with minimal change on the SF-12 (physical health 40.8-39.5, mental health 47.1-46.3) and SE (79-79 %). Based on effect size, the rank order of responsiveness of measures for decliners from high to low was SE (-0.78), Short Form-12 mental health (-0.45), and SF-12 physical health (-0.34). Rank order of responsiveness for improvers was Short Form-12 physical health (-0.11), SF-12 mental health (-0.10), and SE (-0.03).
CONCLUSIONS: Among decliners, measures of disability and quality of life were moderate to highly responsive to change in disease severity. Among improvers, both disability and quality of life were poorly responsive despite UPDRS improvement of comparable magnitude.

Entities:  

Keywords:  Health-related quality of life; Modified Schwab and England activities of daily living; Parkinson’s disease; Short Form-12

Mesh:

Year:  2016        PMID: 27363693     DOI: 10.1007/s11136-016-1351-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  35 in total

1.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

2.  Evaluating measurement responsiveness.

Authors:  M H Liang
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

Review 3.  Understanding disability in Parkinson's disease.

Authors:  Lisa M Shulman
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 4.  Health-related quality-of-life scales in Parkinson's disease: critique and recommendations.

Authors:  Pablo Martinez-Martin; Martine Jeukens-Visser; Kelly E Lyons; C Rodriguez-Blazquez; Caroline Selai; Andrew Siderowf; Mickie Welsh; Werner Poewe; Oliver Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz; Anette Schrag
Journal:  Mov Disord       Date:  2011-07-06       Impact factor: 10.338

5.  Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.

Authors:  Aristide Merola; Maurizio Zibetti; Serena Angrisano; Laura Rizzi; Valeria Ricchi; Carlo A Artusi; Michele Lanotte; Mario G Rizzone; Leonardo Lopiano
Journal:  Brain       Date:  2011-06-11       Impact factor: 13.501

Review 6.  What is the use? Application of the short form (SF) questionnaires for the evaluation of treatment effects.

Authors:  Aline J Pelle; Nina Kupper; Floortje Mols; Peter de Jonge
Journal:  Qual Life Res       Date:  2012-09-14       Impact factor: 4.147

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Predictors and course of health-related quality of life in Parkinson's disease.

Authors:  Elin Bjelland Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Karen Herlofson; Guido Alves
Journal:  Mov Disord       Date:  2008-07-30       Impact factor: 10.338

9.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  3 in total

1.  Dynamics of change in self-reported disability among persons with Parkinson's disease after 2 years of follow-up.

Authors:  Tatjana Gazibara; Darija Kisic-Tepavcevic; Marina Svetel; Aleksandra Tomic; Iva Stankovic; Vladimir Kostic; Tatjana Pekmezovic
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

2.  Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison.

Authors:  Samantha K Holden; Claire E Koljack; Lindsay P Prizer; Stefan H Sillau; Janis M Miyasaki; Benzi M Kluger
Journal:  Parkinsonism Relat Disord       Date:  2019-06-23       Impact factor: 4.891

3.  Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease.

Authors:  Connie Marras; Kelly A Mills; Shirley Eberly; David Oakes; Kelvin L Chou; Matthew Halverson; Sotirios A Parashos; Christopher G Tarolli; Jin-Shei Lai; Cindy J Nowinsky; Oksana Suchowersky; Eric S Farbman; Lisa M Shulman; Tanya Simuni
Journal:  Mov Disord       Date:  2021-05-13       Impact factor: 9.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.